The word molnupiravir is not easy to remember. Much simpler and clearer, however, is the term used by Anthony Fauci, the US immunologist and White House consultant to define the results, announced on October 1, of the trial of the antiviral drug, with the difficult name, against Covid: “Impressive”. So good that the pharmaceutical companies Merck and Ridgeback (which produce molnupiravir) have decided to suspend the trial and ask the Food and Drug Administration, the American body that authorizes the drugs, to give the green light for emergency use. Professor Francesco Scaglione, professor of Pharmacology at the University of Milan and clinical pharmacologist at the Niguarda Hospital he will tell us why this could be a turning point. But, starting from what was recently discovered in Israel, Cristina Marrone del Corriere Salute will explain why it is not yet time to let our guard down.
October 10, 2021 (change October 10, 2021 | 23:54)
© REPRODUCTION RESERVED